Healthcare Dec 23, 2020 11:21 AM (GMT+8) · EqualOcean
Recently, ganlai pharmaceutical, a wholly-owned subsidiary of Geli pharmaceutical, announced that it had completed the administration of asc41 IB phase clinical trial for overweight and obese subjects. Asc41 is a kind of liver targeting precursor drug, and its active component asc41-a is a selective thyroid hormone beta receptor (THR - β) agonist. In this randomized, double-blind, placebo-controlled phase IB clinical study, subjects were overweight and obese subjects with low-density lipoprotein cholesterol (LDL-C) greater than 110 mg / dl. The treatment lasted for 28 days, and the drug was given once a day, 10mg each time. The aim of this study was to evaluate the following indicators: 1) the effect of asc41 on heart health markers, namely low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-C); 2) the safety and tolerance of asc41 tablets; 3) the pharmacokinetic data of asc41 tablets and its active ingredient asc41-a in overweight and obese subjects.